“Lindys Health’s involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life,” states Michael Young, co-founder of Lindus Health. “We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space.”
"This study highlights the core underlying mechanism of action of our ovarian support cells in maturing eggs outside of the body and provides a deeper look into the role that Fertilo plays in promoting high quality egg maturation for IVF treatment," said Dr. Christian Kramme, Chief Scientific Officer of Gameto.
“Lindys Health’s involvement in this study underpins our commitment to helping our partners bring safe and effective dermatological therapies to market. Inflammatory acne can significantly diminish quality of life,” states Michael Young, co-founder of Lindus Health. “We are enthusiastic about the opportunity to leverage our unique technical and service-based capabilities in another dermatology study, building on our vast experience in this space.”
Both companies are ideally positioned to leverage shared resources to accelerate the initiation of the U.S. clinical trial of the SeQuent Please ReX to study the treatment of coronary in-stent restenosis (ISR), which is defined as the gradual re-narrowing of a coronary artery following stent implantation.
The first adjustable, fully visible stent retriever shows superiority over conventional stent retrievers in a multicenter trial. The late-breaking results were recently presented at the International Stroke Conference and published online in the journal Stroke.
NovaSight has announced that it is running a large, pivotal multi-center randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for Amblyopia (Lazy Eye).
The study will rely on Sonde One, a research-based smartphone app, which quickly and objectively detects signs of respiratory symptoms such as chest pain, coughing, or shortness of breath through a six-second voice sample.
The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health.
Clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently published in the Journal of American College of Cardiology: Clinical Electrophysiology.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
